...
首页> 外文期刊>Oncoimmunology. >The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy
【24h】

The nitric oxide radical scavenger carboxy-PTIO reduces the immunosuppressive activity of myeloid-derived suppressor cells and potentiates the antitumor activity of adoptive cytotoxic T lymphocyte immunotherapy

机译:一氧化氮自由基清除剂羧基-PTIO降低了髓样抑制细胞的免疫抑制活性,并增强了过继细胞毒性T淋巴细胞免疫疗法的抗肿瘤活性

获取原文
获取原文并翻译 | 示例
           

摘要

Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) can result in robust and durable antitumor responses. Tumor-infiltrating CTLs produce IFN gamma and mediate antitumor activity, but they simultaneously induce counter-regulatory immunosuppressive mechanisms in the tumor by recruiting monocytic myeloid-derived suppressor cells (MDSCs) that limit their proliferation and effector function. Using a murine model of adoptive immunotherapy for B16 melanoma, we developed a strategy to augment CTL activity by downregulating immunosuppression by MDSCs. Intravenous injection of transgenic pmel-1 CTLs into tumor-bearing mice, resulted in their infiltration into the tumor, but this was accompanied by the accumulation of large numbers of monocytic MDSCs (M-MDSCs). These cells hampered CTL function and reduced their numbers in the tumor. We determined that one mechanism responsible for this immunosuppression was the production of nitric oxide (NO) by MDSCs in the tumor. Therefore, mice were given the NO scavenger carboxy-PTIO (C-PTIO) on the day after CTL transfer. This led to the restoration of impaired proliferative capacity and function of the CTLs, resulting in sustained suppression of tumor growth. Thus, we conclude that CTL therapy can be improved by counter-acting immunosuppression. Targeting NO, one mediator of the immunosuppressive activity of M-MDSCs, may be an appropriate strategy to restore impaired CTL function and improve the efficacy of immunotherapy.
机译:采用细胞毒性T淋巴细胞(CTL)的过继免疫疗法可导致强大而持久的抗肿瘤反应。肿瘤浸润性CTL产生IFNγ并介导抗肿瘤活性,但它们通过募集限制其增殖和效应功能的单核细胞来源的抑制细胞(MDSC)同时诱导肿瘤中的反调节免疫抑制机制。我们使用过继免疫疗法治疗B16黑色素瘤的小鼠模型,开发了一种通过下调MDSC免疫抑制来增强CTL活性的策略。向携带肿瘤的小鼠静脉内注射转基因pmel-1 CTL,导致它们浸润到肿瘤中,但这伴随着大量单核MDSC(M-MDSC)的积累。这些细胞阻碍了CTL的功能并减少了它们在肿瘤中的数量。我们确定造成这种免疫抑制的一种机制是肿瘤中MDSC产生一氧化氮(NO)。因此,在CTL转移的第二天,给小鼠NO清除剂羧基-PTIO(C-PTIO)。这导致受损的CTLs的增殖能力和功能的恢复,导致肿瘤生长的持续抑制。因此,我们得出结论,可以通过反作用免疫抑制来改善CTL治疗。靶向NO是M-MDSCs免疫抑制活性的一种介质,可能是恢复受损CTL功能并提高免疫疗法功效的合适策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号